Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Nat Commun. 2023 Feb 18;14(1):926. doi: 10.1038/s41467-023-36497-x.
A pro-inflammatory intestinal microbiome is characteristic of Parkinson's disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.
促炎肠道微生物组是帕金森病 (PD) 的特征。益生元纤维会改变微生物组,本研究旨在了解益生元纤维在 PD 患者中的应用价值。最初的实验表明,用益生元纤维发酵 PD 患者的粪便会增加有益代谢物(短链脂肪酸,SCFA)的产生,并改变微生物群,表明 PD 微生物群有能力对益生元产生有利的反应。随后,对新诊断的、未用药的(n=10)和接受治疗的 PD 参与者(n=10)进行了一项开放标签、非随机研究,评估了 10 天益生元干预的影响。结果表明,益生元干预在 PD 参与者中耐受良好(主要结果)且安全(次要结果),并与微生物群、SCFA、炎症和神经丝轻链的有益生物学变化相关。探索性分析表明对临床相关结果有影响。这项概念验证研究为 PD 患者使用益生元纤维进行安慰剂对照试验提供了科学依据。ClinicalTrials.gov 标识符:NCT04512599。